Joschka Hellmeier
Vienna University of Technology
11 Papers
1 Citations
Joschka Hellmeier is an academic researcher from Vienna University of Technology. The author has contributed to research in topics: Chemistry & Ligand (biochemistry). The author has an hindex of 2, co-authored 5 publications.
Chat about Author
Papers
DNA origami demonstrate the unique stimulatory power of single pMHCs as T cell antigens.
Joschka Hellmeier,René Platzer,Alexandra S. Eklund,Alexandra S. Eklund,Thomas Schlichthaerle,Thomas Schlichthaerle,Andreas Karner,Viktoria Motsch,Magdalena C. Schneider,Elke Kurz,Victor Bamieh,Mario Brameshuber,Johannes Preiner,Ralf Jungmann,Ralf Jungmann,Hannes Stockinger,Gerhard J. Schütz,Johannes B. Huppa,Eva Sevcsik +18 more
TL;DR: In this paper, a biomimetic interface based on laterally mobile functionalized DNA origami platforms was proposed for nanoscale control over ligand distances without interfering with the cell-intrinsic dynamics of receptor clustering.
84
Strategies for the Site-Specific Decoration of DNA Origami Nanostructures with Functionally Intact Proteins.
Joschka Hellmeier,René Platzer,Vanessa Mühlgrabner,Magdalena C. Schneider,Elke Kurz,Gerhard J. Schütz,Johannes B. Huppa,Eva Sevcsik +7 more
TL;DR: In this paper, the authors applied single molecule fluorescence microscopy in combination with a cell biological functional assay to systematically evaluate different strategies for the site-specific decoration of DNA origami structures, focusing on efficiency, stoichiometry, and protein functionality.
28
Balancing the Nanoscale Organization in Multivalent Materials for Functional Inhibition of the Programmed Death-1 Immune Checkpoint.
Kaltrina Paloja,Jorieke Weiden,Joschka Hellmeier,Alexandra S. Eklund,Susanne C. M. Reinhardt,Ian A Parish,Ralf Jungmann,Maartje M. C. Bastings +7 more
TL;DR: Data show that PD-1 nano-organization has profound effects on ligand interaction and that the valency of PD-1 molecules modulates the effectiveness in restoring T cell function, and presents alternative design strategies for immune-engineering.
5
CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T-cell therapy in cancer
Ashwathi Puravankara Menon,Helena Villanueva,Daniel Meraviglia-Crivelli,Hisse M. van Santen,Joschka Hellmeier,Angelina Zheleva,Francesca Nonateli,Timo Peters,Tassilo Wachsmann,Mercedes Hernandez-Rueda,Johannes B Huppa,Gerhard J. Schütz,Eva Sevcsik,Beatriz Moreno,Fernando Pastor +14 more
- 01 Apr 2024
TL;DR: CD3 aptamers enhance tumor-reactive T cell expansion and persistence for adoptive T-cell therapy in cancer by activating the CD3/TCR complex, overcoming limitations of traditional CD3 agonistic antibodies and improving treatment efficacy.
1